Categories: News

Genuity Science Wins 2021 BIG Innovation Award for Novel Genome Sequencing Approach

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOSTON, Jan. 12, 2021 /PRNewswire/ — Genuity Science, a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.

Genuity Science was honored for placing innovation front and center as it continues to change the drug development process by using a combination of population-scale genetics; a scalable, flexible software platform that addresses genomic big data challenges; and a new, groundbreaking approach to artificial intelligence (AI). In collaboration with Professor Michael Simons and his team at Yale University Medical School, the Genuity Science Advanced AI Research Laboratory used a new generative AI approach to discover, in mice studies, a novel pathobiological mechanism that causally underpins aortic aneurysm.

Genuity Science’s AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level. Through a combination of single-cell biology and RNA sequencing, they discovered a group of abnormal cells that drive thoracic aortic aneurysm. By disrupting this process, they could reduce the incidence of the aneurysm altogether, giving researchers an unprecedented advantage in understanding that could better focus drug development efforts in humans.

“We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms,” said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science. “This class of AI methods is changing the drug development process by providing the means to identify causal molecular underpinnings of diseases. This has the potential to bring down drug discovery costs. It can also speed up development timelines and improve treatment options for rare and common diseases.”

“More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy, and comfortable,” said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. “We are thrilled to be honoring Genuity Science as they are one of the organizations leading this charge and helping humanity progress.”

The BIG Innovation Awards recognize organizations, products, and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.

About Business Intelligence Group

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

About Genuity Science

Genuity Science is a data, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma and life sciences companies to offer deep end-to-end drug target and biomarker discovery programs aimed at catalyzing precision health and improving the quality of life for patients around the world. Genuity’s programs include population-scale, disease-specific data sourcing with detailed longitudinal clinical information, high-quality sequencing, a uniquely scalable genomic and clinical database architecture and tools for analyzing large datasets, and advanced artificial intelligence (AI). The company operates an advanced CAP-accredited laboratory in Dublin, Ireland, and is deeply committed to responsible and compliant data stewardship across its global offices. For more information, see www.genuitysci.com.

View original content:http://www.prnewswire.com/news-releases/genuity-science-wins-2021-big-innovation-award-for-novel-genome-sequencing-approach-301206813.html

SOURCE Genuity Science

Staff

Recent Posts

New leadership for the Canadian Institute of Actuaries in its 60th year

Ottawa, Ontario--(Newsfile Corp. - May 29, 2025) - Angelita Graham is taking on the role…

1 hour ago

Nordic joins the ServiceNow Reseller and Partner Programs to accelerate digital transformation for healthcare organizations

MADISON, Wis., May 29, 2025 /PRNewswire/ -- Nordic® today announced it has joined the ServiceNow Partner…

1 hour ago

HerMD Launches Virtual Care Platform, Expanding Access to Specialized Women’s Healthcare

Scheduling Now Open; Appointments Begin June 2, 2025 CINCINNATI, May 29, 2025 /PRNewswire/ -- HerMD,…

1 hour ago

MarketsandMarkets’ 360Quadrants Recognizes Top Startups and SMEs in the Gold Nanoparticles Quadrant Report 2025

DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- 360Quadrants has released its latest Gold Nanoparticles Startups/SMEs…

1 hour ago

Highmark Health revenue grows 11% year over year to $8 billion; reports $13 million net income in first quarter of 2025

Allegheny Health Network reports 10% revenue growth, $8 million operating income, more-than-doubles EBITDA year-over-yearHighmark Health…

1 hour ago

Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- The global Electronic Lab Notebook Market, valued at…

1 hour ago